Medical/Pharmaceuticals
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15 t...
2024-11-08 22:00
3158
Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024
Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving pembrolizumab SEOUL, South Korea, Nov. 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...
2024-11-08 22:00
3604
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
HANOI, Vietnam, Nov. 8, 2024 /PRNewswire/ -- DND International Eye Hospital is the first facility inVietnam to implement SMILE Pro technology, an advanced FDA-approved eye refractive surgery method. It is also an ideal destination for international tourists seeking to combine travel with refracti...
2024-11-08 20:11
7120
Samsung Biologics earns ISO certifications in recognition of business excellence
* The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security * Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDM...
2024-11-08 20:00
2202
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Dizal (SSE:68...
2024-11-08 18:01
2099
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...
2024-11-08 17:45
1895
Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
* Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers * Infinitopes' proprietary vector delivery sys...
2024-11-08 16:30
2311
Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
* Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers * Infinitopes' proprietary vector delivery sys...
2024-11-08 16:30
2001
WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards
SHANGHAI and SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), is ...
2024-11-08 11:27
2825
InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC
NANJING, China, Nov. 7, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, is presenting preclinical data at 15th Annual World ADC Conference in San Diego regarding ifebemtinib (ifebe, IN1...
2024-11-08 10:40
2083
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held inHouston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, ...
2024-11-08 08:20
2030
United Imaging Receives First Approval in Canada
The uMI Panorama™ is being readied for sale in Canada and will ship from the company'sHouston-based North American headquarters. HOUSTON, Nov. 7, 2024 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has received Health Canada approval for ...
2024-11-07 22:00
2021
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk
National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk assessment. PLYMOUTH MEETING, Pa., Nov. 7, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network...
2024-11-07 21:37
2126
New Meta-Analysis Strengthens Evidence That Nuts May Lower Cardiovascular Risk
BARCELONA, Spain, Nov. 7, 2024 /PRNewswire/ -- A recent systematic review and meta-analysis funded by the International Nut and Dried Fruit Council (INC) has just been published in the prestigious scientific journalNutrition, Metabolism and Cardiovascular Diseases.[1] The study showed that curren...
2024-11-07 20:40
3131
Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity
* Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via subcutaneous(SQ) injection, demonstrated a half-life of 21 days, supporting once-monthly administration in patients with obesity * ...
2024-11-07 19:30
3443
MGI Tech Partners with the Human Cell Atlas to Further Advance Worldwide Human Cell Mapping Efforts
SHENZHEN, China, Nov. 7, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced a commercial partnership with Human Cell Atlas (HCA) consortium to further accelerate the human cell mapping...
2024-11-07 19:24
2136
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3tri-specific T-cell engager antibody OAKLAND, Calif. and NANJING, China, Nov. 7, 2024 /PRNewswire/ -- Aditum Bio and Leads Biolabs today announced the formation of Oblenio Bio, which is being f...
2024-11-07 16:29
2918
Fosun Attends CIIE for the Seventh Time - Guo Guangchang: Confident that China's High-Level Openness is a Historical Opportunity
HONG KONG, Nov. 7, 2024 /PRNewswire/ -- On November 5, the 7th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center inShanghai. As a seven-time attendee of the CIIE, Fosun showcased the latest achievements in innovation and global operations at its Fosun...
2024-11-07 13:18
3337
Approx. USD 4.0 M Invested in Product Development for NTDs - GHIT's First Investment in the Development of Diagnostics for Trachoma
TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 578 million ( USD 4.0 million1) in four projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.2 GH...
2024-11-07 10:00
2164
BRACCO TRIPLES PRODUCTION OF ITS INNOVATIVE CONTRAST AGENT FOR ULTRASOUND IN GENEVA, INAUGURATING A SECOND FACILITY
The significant investment increases the production of CEUS microbubbles The imaging platform for ultrasound, the fruit of Bracco's research, assists doctorsall over the world with more accurate diagnostic data, improving patients' quality of life and facilitating personalized treatment plans PL...
2024-11-06 22:42
2639
Week's Top Stories
Most Reposted
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 322 media titles]
2026-02-02 10:00
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 322 media titles]
2026-01-29 15:06
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 310 media titles]
2026-02-03 11:00
Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 303 media titles]
2026-02-03 12:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 286 media titles]
2026-02-01 19:35